tiprankstipranks
Trending News
More News >
Alaunos Therapeutics (TCRT)
NASDAQ:TCRT

Alaunos Therapeutics (TCRT) AI Stock Analysis

Compare
681 Followers

Top Page

TC

Alaunos Therapeutics

(NASDAQ:TCRT)

Rating:45Neutral
Price Target:
Alaunos Therapeutics' overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.

Alaunos Therapeutics (TCRT) vs. SPDR S&P 500 ETF (SPY)

Alaunos Therapeutics Business Overview & Revenue Model

Company DescriptionAlaunos Therapeutics (TCRT) is a biotechnology company focused on the development and commercialization of innovative, cell-based cancer immunotherapies. Operating within the healthcare and biotechnology sectors, the company is committed to advancing its proprietary T-cell receptor (TCR) therapy platform. This platform is designed to harness the power of the body's immune system to target and destroy cancer cells, offering potential treatments for a variety of solid tumor cancers.
How the Company Makes MoneyAlaunos Therapeutics generates revenue primarily through the development and commercialization of its TCR-based therapies. The company may earn income through collaboration agreements, research and development partnerships, and potential licensing deals with larger pharmaceutical companies. These partnerships can include milestone payments and royalties based on the successful development and commercialization of therapies. Additionally, Alaunos may seek funding through private and public investments to support ongoing research and clinical trials, although these do not directly constitute revenue.

Alaunos Therapeutics Financial Statement Overview

Summary
Alaunos Therapeutics faces significant financial challenges with continuous losses, negative cash flows, and a declining equity base. While the absence of debt reduces financial risk, the lack of profitability and need for external funding highlight the company's precarious financial position.
Income Statement
30
Negative
Alaunos Therapeutics has struggled with profitability, evidenced by its negative net income and EBIT margins over recent years. Despite a marginal increase in revenue in the latest year, the company remains unprofitable, with widening losses. The gross profit margin is effectively non-existent due to minimal revenue.
Balance Sheet
40
Negative
The company has a relatively strong equity position with no debt, reflected in a debt-to-equity ratio of zero. However, its equity ratio has declined due to shrinking stockholders' equity, which signals potential financial instability. Return on equity is not meaningful due to persistent losses.
Cash Flow
35
Negative
Alaunos Therapeutics reports negative free cash flow, indicating cash outflows from operations continue to exceed cash inflows. Although operating cash flow has improved from previous years, the company still requires substantial external financing to support operations.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
10.00K10.00K5.00K2.92M398.00K0.00
Gross Profit
9.00K10.00K-4.80M163.00K-342.00K-1.13M
EBIT
-4.16M-4.81M-34.27M-35.10M-77.55M-80.36M
EBITDA
-4.07M-4.68M-30.90M-31.82M-74.97M-78.85M
Net Income Common Stockholders
-4.07M-4.68M-35.14M-37.60M-76.89M-78.85M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.09M1.09M6.06M39.06M76.05M115.07M
Total Assets
2.75M2.75M8.26M64.94M94.86M146.34M
Total Debt
0.000.000.0019.51M29.36M4.81M
Net Debt
-1.09M-1.09M-6.06M-19.55M-46.69M-110.25M
Total Liabilities
692.00K692.00K1.96M26.38M36.81M22.36M
Stockholders Equity
2.06M2.06M6.31M38.55M58.06M123.98M
Cash FlowFree Cash Flow
25.85M-4.97M-30.34M-29.45M-64.79M-66.79M
Operating Cash Flow
23.61M-4.97M-30.14M-29.23M-61.47M-57.01M
Investing Cash Flow
0.000.001.35M-193.00K-3.32M-9.78M
Financing Cash Flow
-24.95M0.00-18.14M6.37M25.78M102.12M

Alaunos Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.69
Price Trends
50DMA
2.58
Positive
100DMA
2.10
Positive
200DMA
2.23
Positive
Market Momentum
MACD
0.02
Positive
RSI
51.80
Neutral
STOCH
88.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRT, the sentiment is Positive. The current price of 2.69 is below the 20-day moving average (MA) of 2.73, above the 50-day MA of 2.58, and above the 200-day MA of 2.23, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.80 is Neutral, neither overbought nor oversold. The STOCH value of 88.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCRT.

Alaunos Therapeutics Risk Analysis

Alaunos Therapeutics disclosed 58 risk factors in its most recent earnings report. Alaunos Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We could lose our listing on the Nasdaq Capital Market if we do not maintain our stockholders' equity. The loss of our Nasdaq listing would in all likelihood make our common stock significantly less liquid and adversely affect its value, including a total loss of value. Q3, 2024
2.
Our small molecule obesity drug program is very early stage and may not provide an alternative to the terminated TCR-T program in order to enable the Company to continue operations. Q3, 2024
3.
For our small molecule oral obesity program or should we resume development of our product candidates of our TCR-T program, we may not be able to commercialize them, generate significant revenues, or attain profitability. Q3, 2024

Alaunos Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$5.25B3.24-45.38%2.81%16.79%-0.06%
45
Neutral
$4.00M-100.01%6.87%
45
Neutral
$4.57M-139.06%80.00%86.70%
43
Neutral
$4.78M-53.16%-1.56%5.01%
41
Neutral
$3.69M-714.96%978.39%69.65%
29
Underperform
$3.16M-748.05%-100.00%76.55%
28
Underperform
$2.89M-120.01%97.84%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TCRT
Alaunos Therapeutics
2.69
-7.61
-73.88%
TOVX
Theriva Biologics
0.46
-6.23
-93.12%
SONN
Sonnet BioTherapeutics Holdings
1.17
-11.95
-91.08%
OGEN
Oragenics
3.70
-47.90
-92.83%
WINT
Windtree Therapeutics
0.66
-163.84
-99.60%
XBIO
Xenetic Biosciences
3.07
-0.91
-22.86%

Alaunos Therapeutics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Alaunos Therapeutics Board Opts for Equity Compensation
Neutral
Apr 15, 2025

On April 13, 2025, Alaunos Therapeutics‘ Board of Directors decided to receive their deferred board service fees in equity instead of cash, as per the company’s policy. The deferred fees, totaling $139,000 from late 2024 to early 2025, were compensated with 38,269 shares of common stock and 10,904 stock options, reflecting a strategic move to align the board’s interests with the company’s performance.

Spark’s Take on TCRT Stock

According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.

Alaunos Therapeutics is in a challenging financial position due to ongoing losses and negative cash flows. While technical indicators suggest positive momentum, the lack of profitability and unattractive valuation metrics weigh heavily on the stock. The absence of debt provides some financial flexibility, but the need for external funding remains a critical concern.

To see Spark’s full report on TCRT stock, click here.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.